查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466102

胜胜肽治疗市场：按技术、药物类别、给药途径、应用、最终用户、製造类型划分 - 2024-2030 年全球预测

Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年胜胜肽治疗市场规模为330.6亿美元，预计2024年将达357.6亿美元，2030年将达579.7亿美元，复合年增长率为8.35%。

胜肽疗法使用短链氨基酸来治疗或控制多种疾病和病症。这些生物活性分子具有独特的性质，使其成为高效能药物开发和药物研究的选择。包括癌症和糖尿病在内的慢性疾病的扩散增加了对有效治疗方案的需求，以及更好地了解蛋白质-蛋白质相互作用以实现标靶治疗。由于研发活动投资增加以及治疗候选药物临床管道不断增加，新型胜肽疗法正在开发中。然而，胜肽固有的不稳定性和高製造成本会对胜胜肽疗法的开发产生负面影响。此外，药物输送系统的最新进展和新胜胜肽的开发预计将扩大胜肽的潜在应用。

主要市场统计
基准年[2023] 330.6亿美元
预测年份 [2024] 357.6亿美元
预测年份 [2030] 579.7亿美元
复合年增长率（%） 8.35%

技术：在复杂胜胜肽的合成中增加固相方法的利用率

混合相方法结合了液相和固相合成的特征，以提高效率和可扩展性，同时保持胜胜肽生产的高纯度水平。该方法是开发复杂或胜肽的首选方法，胜肽它克服了与传统方法相关的挑战。液相胜肽合成 (LPPS) 使用各种化学反应将溶液中的胺基酸结合。与固相方法相比，LPPS具有相对较快的反应速率，使其适合短链至中链胜胜肽的小规模生产。固相胜胜肽合成 (SPPS) 涉及将第一个胺基酸连接到固体树脂支撑物上，然后依序添加后续胺基酸。这种方法受到广泛的青睐，因为它可以合成更长、更复杂的胜肽，更容易精製，并且可扩展。混合相技术结合了胜肽。溶液相合成主要用于短链至中链胜胜肽的小规模生产。固相胜胜肽合成受到广泛青睐，因为它提供了一种易于精製和规模化的选择，同时提供了合成更长、更复杂胜胜肽的多功能性。

药物类别：第 1 型和第 2 型糖尿病患者对胰岛素调节葡萄糖代谢的需求不断增加

促肾上腺皮质激素（ACTH）是一种由脑下垂体前叶分泌和产生的多肽激素。在治疗上，促肾上腺皮质激素用于治疗某些需要刺激皮质醇产生的疾病。这包括治疗对皮质醇水平升高有反应的疾病，例如肾上腺功能不全和某些发炎疾病。治疗时使用的外源性製剂直接刺激肾上腺皮质，模拟ACTH的作用发生，刺激皮质醇的分泌，进而发挥发炎和活化作用。抑钙素在钙和磷代谢中很重要。在人类中，它主要由甲状腺滤泡旁细胞产生。鲑鱼衍生或合成的抑钙素的治疗形式主要用于治疗停经后骨质疏鬆症、佩吉特氏症和高钙血症。透过抑制破骨细胞活性，抑钙素可抑制骨吸收并降低血钙浓度。胰岛素是一种基本的肽激素，对于调节胰臟β细胞产生的葡萄糖代谢非常重要，促进肌肉、肝臟和脂肪细胞从血液中摄取葡萄糖。在治疗方面，胰岛素对于第 1 型和第 2 型糖尿病的治疗至关重要。亮丙瑞林是促性腺激素分泌释放激素 (GnRH) 的合成类似物，连续给药时可充当有效的促性腺激素分泌分泌抑制剂。它用于治疗荷尔蒙反应性癌症，例如男性前列腺癌和女性子宫内膜异位症和子宫肌瘤。Octreotide是天然荷尔蒙生长抑制素的合成胜肽类似物，具有相似但更持久的药理作用。Octreotide主要用于治疗肢端肥大症，其特征是生长激素分泌过多，这是由某些类型的激素分泌肿瘤引起的疾病，例如类癌和血管活性肠胜肽分泌腺瘤（VIP肿瘤）。Octreotide透过抑制多种荷尔蒙的分泌来发挥作用，包括生长激素、胃泌素、胰岛素和升糖素。加压素，也称为抗利尿激素（ADH），是肽激素。 ADH 透过增加肾臟集合管中的水分重吸收来调节体内的水分储存。在治疗上，增压素及其类似物用于治疗糖尿病性肾衰竭（其特征是过度干燥和产生大量稀尿），并由于其血管收缩作用而用于治疗静脉曲张出血。

给药途径：静脉注射由于其即时效果和有效性而越来越多地在急诊医院中使用。

胜肽疗法的静脉注射直接进入血液，促进即时生物有效性。此途径对于胃肠道吸收较差或经由其他途径给药时容易代谢的胜胜肽特别有利。静脉注射对于用于急诊护理或胜肽快速起效的胜胜肽至关重要。然而，管理需要临床基础设施和熟练的工作人员，这可能会限制其对门诊病人和慢性治疗的适用性。鼻腔和肺部给药为胜胜肽治疗提供了一种非侵入性给药方法，可以有效吸收并针对特定症状立即起效。鼻腔给药特别适合利用鼻-脑途径标靶中枢神经系统的胜肽。肺部给药是针对呼吸系统疾病的胜肽的理想选择，可以直接输送到肺部。这两种方法都绕过首过代谢，因此有可能提高治疗的生物有效性。口服给药因其方便性、患者依从性和成本效益而成为首选的给药途径。胜肽在胃肠道中容易被酵素降解，且穿过肠上皮的渗透性较低。酵素抑制剂、渗透增强剂和奈米颗粒递送系统等製药科学的进步，为在不同程度上克服这些障碍提供了潜力。胜胜肽疗法的经皮给药不需要注射或特殊的吸入装置，因此描述了疗效和患者依从性之间令人信服的平衡。此途径对于需要缓释性药物释放的慢性疾病特别有利。微针、离子电渗透疗法和超音波等经皮技术的进步改善了胜肽穿过皮肤屏障的转运。增强皮肤渗透性和胜肽稳定性的製剂策略是经皮製剂成功开发的核心。

应用：扩大胜肽疗法在循环系统疾病的应用，模拟内源性胜肽参与血压调节的作用

在循环系统疾病中，胜肽疗法已被使用，因为其精确的作用机制使其能够有效调节血管功能、血压和凝血途径。抗凝血胜肽用于预防血栓症，血栓形成是心肌梗塞和中风的重要危险因子。对于胃肠道 (GI) 疾病，胜肽疗法提供了一种标靶治疗选择。此外，模拟或抑制胃肠激素的胜胜肽可以调节胃肠道内的运动、吸收和分泌，并解决各种疾病的症状。其有针对性的行动可以帮助控制荷尔蒙失衡和胃肠道相关疾病破坏引起的症状。胜肽疗法为传染病的治疗带来了一种新方法，尤其是在抗生素抗药性日益增强的时代。胜肽(AMP) 具有广泛的抗菌活性，可透过破坏某些细菌、真菌甚至病毒的细胞膜来作用于它们。其作用机制降低了产生抗药性细菌的可能性，使其成为对抗抗药性感染疾病的重要候选者。在神经系统疾病中，正在研究穿透血脑障壁（BBB）并直接对中枢神经系统（CNS）发挥神经保护作用的可能性。胜胜肽针对特定的神经传导物质系统，为治疗阿兹海默症、帕金森氏症和多发性硬化症等疾病提供了机会。在肿瘤学中，胜胜肽治疗是一个快速成长的领域，人们正在研究胜胜肽的抗癌特性，包括对癌细胞的直接细胞毒性作用、抑制血管生成以及标靶药物传递的载体。肿瘤归巢胜肽可以选择性地将化疗药物和放射性核素递送至癌细胞，最大限度地减少对健康组织的损害并提高治疗效果。

最终使用者：扩大胜肽疗法在医院和诊所的使用，以解决和管理病患病情

在医院和诊所，胜肽疗法主要用于直接患者治疗。它用于治疗许多疾病，包括癌症、代谢失调、心血管疾病和感染疾病。由于其高特异性、有效性和相对低的毒性，胜肽药物代表了一种标靶治疗方法，与传统的小分子药物相比，它具有更高的疗效和更少的副作用。随着胜肽工程和药物传输技术的进步，胜肽药物在医院和诊所的应用不断发展，提高了其疗效和患者依从性。长期照护机构优先考虑确保患者长期健康的治疗，通常注重管理而不是治疗。长期照护机构使用的胜肽治疗必须最大限度地减少副作用，并降低给药频率，以适应护理环境。实验室在胜肽治疗开发的早期阶段至关重要。研究人员致力于识别新的生物活性胜胜肽，阐明其作用机制，并优化其治疗用途的特性。为此，我们将利用尖端的分子生物学、生物化学和药理技术来设计、合成和评估候选胜胜肽的活性。

製造类型：由于专业製造能力和快速扩大生产规模的需要，增加了 CMO 的招聘

受託製造厂商为没有必要的内部製造设施或选择外包製造以专注于其核心竞争力的製药和生物技术公司提供胜肽疗法製造的基本服务。 CMO 提供各种服务，从用于研究的小规模胜肽合成到用于商业用途的大规模生产。 CMO 拥有高效能、合规生产胜胜肽治疗药物所需的技术专长、先进技术和监管知识。内部製造是指製药或生技公司拥有製造胜胜肽疗法的设备和资源。这种方法使公司能够直接控制生产过程、品管和供应链管理，从而潜在地降低与依赖外部供应商相关的风险。大型製药公司有财力投资必要的基础设施和技术人员，并且通常建立内部生产设施。这种模式有利于研发活动和製造的更紧密整合，这对于快速发展的治疗领域是有利的。

区域洞察

在美洲，由于製药业的成熟、研究活动的增加以及核准胜肽药物数量的增加，胜肽治疗市场正在发展。该地区的专利活动引人注目，多家大型製药公司的总部均设在该地区。近年来，对创新胜胜肽製剂的投资有所增加，显示出新治疗方法的巨大市场潜力。慢性病盛行率的上升、医疗保健基础设施的改善以及对胜胜肽治疗的认识不断提高正在推动亚太地区胜肽治疗市场的成长。此外，高效、可扩展且具有成本效益的胜胜肽生产合成策略正在取得进展和发展，而胜肽疗法的全球普及预计将会增加。由于支持生物技术创新并资助与胜肽治疗相关的研究计划的法律规范，胜肽治疗市场正在欧洲、中东和非洲地区发展。欧盟 (EU) 代表了胜胜肽疗法的成熟市场，并得到全面的医疗保健系统和对先进治疗方案的高度认识的支持。透过欧洲药品管理局 (EMA) 的欧盟法规结构有助于核准和监控胜胜肽类药物。由于研究活动的活性化和对先进治疗方案认识的提高，非洲地区的胜肽治疗市场目前正在稳步成长。

FPNV定位矩阵

FPNV定位矩阵对于评估胜胜肽治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对胜胜肽治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、碎片化主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.胜肽治疗市场的市场规模与预测是多少？

2. 在胜胜肽治疗市场的预测期内，我们应该考虑投资哪些产品和应用？

3.胜肽治疗市场的技术趋势和法规结构是什么？

4.胜肽治疗市场主要厂商的市场占有率是多少？

5. 进入胜胜肽治疗市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和有效治疗方法的需求
      • 胜肽在美容皮肤科的快速应用
    • 抑制因素
      • 回顾胜胜肽治疗的不良反应
    • 机会
      • 持续进行研究和开发活动，在世界各地开发新的胜胜肽
      • 向个人化医疗的转变和胜肽生物标记的鑑定
    • 任务
      • 胜胜肽治疗药物的生产复杂性与生物利用度问题
  • 市场区隔分析
    • 技术：在复杂胜胜肽的合成中更多地使用固相方法
    • 药物类别：1 型和 2 型糖尿病患者对胰岛素调节葡萄糖代谢的需求增加
    • 给药途径：在急性医院护理环境中，由于即时和有效性，越来越多地采用静脉注射
    • 应用：扩大胜肽疗法在心血管疾病的应用，模拟内源性胜肽参与血压调节的作用
    • 最终使用者：扩大胜肽疗法在医院和诊所的使用，以解决和管理病患病情
    • 製造类型：由于需要专业製造能力和快速扩大生产规模的能力，增加了 CMO 的招聘
  • 市场趋势分析
    • 扩大药品研发活动并增加政府投资以加强美洲的医疗领域
    • 亚太地区对先进研究设施和技术的大量公共和私人投资
    • 加强胜肽製造能力，开拓新的应用领域以及主要参与企业在欧洲、中东和非洲的存在
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章胜胜肽治疗市场：依技术分类

  • 介绍
  • 混合相
  • 液相
  • 固相

第七章胜胜肽治疗市场：依药物类别

  • 介绍
  • 促肾上腺皮质激素
  • 抑钙素
  • 胰岛素
  • 亮丙瑞林
  • Octreotide
  • 加压素

第八章胜胜肽治疗市场：依给药途径

  • 介绍
  • 静脉注射
  • 鼻/肺给药
  • 口服给药
  • 经皮

第九章胜胜肽治疗市场：依应用分类

  • 介绍
  • 心血管疾病
  • 胃肠道疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学

第10章胜胜肽治疗市场：依最终用户分类

  • 介绍
  • 医院/诊所
  • 长期照护设施
  • 实验室

第十一章按製造类型胜肽治疗市场

  • 介绍
  • 合约製造组织
  • 公司内部

第十二章美洲胜胜肽治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太胜胜肽治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲胜胜肽治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析

第16章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-030EE4851583

[196 Pages Report] The Peptide Therapeutics Market size was estimated at USD 33.06 billion in 2023 and expected to reach USD 35.76 billion in 2024, at a CAGR 8.35% to reach USD 57.97 billion by 2030.

Peptide therapeutics use short chains of amino acids to treat or control various diseases and medical conditions. These biologically active molecules possess unique properties, making them an efficient drug development and pharmaceutical research option. The surging prevalence of chronic diseases, including cancer and diabetes, is raising the need for effective treatment options and an improved understanding of protein-protein interactions leading to targeted therapies. The growing investment in research & development activities and a robust clinical pipeline with therapeutic candidates result in novel peptide therapeutics being developed. However, the inherent instability of peptides and the high cost of manufacturing peptides may adversely impact the development of peptide therapeutics. Moreover, recent developments in drug delivery systems and the development of new peptides are expected to expand the potential applications for peptides.

KEY MARKET STATISTICS
Base Year [2023] USD 33.06 billion
Estimated Year [2024] USD 35.76 billion
Forecast Year [2030] USD 57.97 billion
CAGR (%) 8.35%

Technology: Rising utilization of solid phase approach for synthesis of complex peptides

The hybrid phase approach combines liquid-phase and solid-phase synthesis features to enhance efficiency and scalability while maintaining high purity levels for peptide production. This technique is favored while developing complex or large peptides due to its ability to overcome challenges associated with traditional methods. Liquid phase peptide synthesis (LPPS) involves coupling amino acids in solution using various chemical reactions. LPPS is suitable for small-scale production of short to medium-length peptides due to its relatively fast reaction rates compared to solid-phase methods. Solid phase peptide synthesis (SPPS) involves attaching the first amino acid to a solid resin support, followed by the sequential addition of subsequent amino acids. This method is widely preferred due to its ability to synthesize longer and more complex peptides and ease of purification and scalability. Hybrid phase technology is preferred for developing large or complex peptides due to its combined advantages from liquid and solid phases. Liquid phase synthesis is primarily used for small-scale, short- to medium-length peptide production. Solid-phase peptide synthesis is widely favored due to its versatility in synthesizing longer and more complex peptides while offering easy purification and scalability options.

Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes

Adrenocorticotropic hormone (ACTH) is a polypeptide hormone secreted and produced by the anterior pituitary gland. Therapeutically, ACTH is utilized in managing certain disorders where there is a need to stimulate cortisol production. This includes treatment for conditions such as adrenal insufficiency and certain inflammatory disorders that respond to increased cortisol levels. The exogenous form used in therapy provides a direct stimulus to the adrenal cortex by simulating the action of occurring ACTH, encouraging it to secrete cortisol, thereby exerting anti-inflammatory and immunostimulatory effects. Calcitonin is critical in calcium and phosphorus metabolism. It is produced in humans primarily by the parafollicular thyroid gland cells. Therapeutic forms of calcitonin, derived from salmon or synthetically produced, are utilized primarily in treating postmenopausal osteoporosis, Paget's disease, and hypercalcemia. By inhibiting osteoclast activity, calcitonin reduces bone resorption, thereby decreasing blood calcium levels. Insulin is a fundamental peptide hormone critical for regulating glucose metabolism produced by the beta cells of the pancreas, facilitating glucose uptake from the blood into the muscle, liver, and fat cells. In the therapeutic context, insulin is vital in managing diabetes mellitus, both type 1 and type 2, where the body's ability to produce or respond to insulin is impaired. Leuprorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) and functions as a potent inhibitor of gonadotropin secretion when used in continuous administration. It is employed in the treatment of hormone-responsive cancers such as prostate cancer in men and endometriosis and uterine fibroids in women. Octreotide is a synthetic octapeptide analog of the natural hormone somatostatin, possessing similar but longer-lasting pharmacological effects. It is primarily used in the management of acromegaly, a condition characterized by excess production of growth hormone, and in the control of symptoms caused by certain types of tumors that secrete hormones, such as carcinoid tumors and vasoactive intestinal peptide-secreting adenomas (VIPomas). Octreotide works by inhibiting the secretion of various hormones, including growth hormone, gastrin, insulin, and glucagon. Vasopressin, also referred to as antidiuretic hormone (ADH), is a peptide hormone that is secreted by the posterior pituitary gland and produced by the hypothalamus. ADH is critical in regulating the body's water retention by increasing water reabsorption in the kidney's collecting ducts. In a therapeutic setting, vasopressin and its analogs are used to treat diabetes insipidus, a condition characterized by excess thirst and the production of large amounts of diluted urine, and for managing variceal bleeding due to its vasoconstrictive properties.

Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings

Intravenous (IV) administration of peptide therapeutics ensures direct delivery into the bloodstream, facilitating immediate bioavailability. This route is particularly advantageous for peptides that are poorly absorbed through the gastrointestinal tract or extensively metabolized when administered by other routes. IV administration is critical for peptides used in acute care settings or where rapid onset of action is necessary. However, it requires clinical infrastructure and skilled personnel to administer, potentially limiting its applicability to outpatient settings or chronic treatments. Nasal & pulmonary routes offer non-invasive administration alternatives for peptide therapeutics, capable of providing efficient absorption and immediate action for certain conditions. Nasal administration is particularly suited for peptides targeting the central nervous system, leveraging the nose-to-brain pathway. Pulmonary administration is ideal for peptides intended for respiratory ailments, allowing direct delivery to the lungs. Both methods bypass first-pass metabolism, potentially increasing the therapeutic's bioavailability. Oral administration is a preferred route for drug delivery, attributed to its convenience, patient compliance, and cost-effectiveness. Peptides are subject to enzymatic degradation within the gastrointestinal tract and suffer from poor permeability across the intestinal epithelium. Advances in pharmaceutical sciences, such as enzyme inhibitors, permeation enhancers, and nanoparticle delivery systems, have shown promise in overcoming these hurdles, albeit with varying degrees of success. Transdermal delivery of peptide therapeutics offers a compelling balance between efficacy and patient compliance, eliminating the need for injections or specialized inhalation devices. This route is particularly advantageous for chronic conditions requiring sustained release of medication. Advances in transdermal technologies, including microneedles, iontophoresis, and ultrasound, have improved the transport of peptides across the skin barrier. Formulation strategies that enhance skin permeability and peptide stability are central to the successful development of transdermal peptide therapeutics.

Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation

In cardiovascular disorders, peptide therapeutics have been used for their precise mechanisms of action, which can effectively modulate vascular function, blood pressure, and coagulation pathways. Anticoagulant peptides are utilized to prevent thrombosis, a critical risk factor for myocardial infarction and stroke. In gastrointestinal (GI) disorders, peptide therapeutics present an avenue for targeted treatment options. In addition, peptides that mimic or inhibit gastrointestinal hormones can regulate motility, absorption, and secretion within the GI tract, addressing symptoms of various disorders. Their targeted action can aid in managing conditions stemming from hormonal imbalances or disruptions in GI-related disorders. Peptide therapeutics bring a novel approach to managing infectious disorders, especially in an era of increasing antibiotic resistance. Antimicrobial peptides (AMPs) offer a broad-spectrum antimicrobial activity, targeting bacteria, fungi, and even some viruses by disrupting their cellular membranes. Their mode of action reduces the likelihood of resistance development, making them crucial contenders in the fight against drug-resistant infections. In neurological disorders, peptide therapeutics are being explored for their potential for crossing the blood-brain barrier (BBB) and delivering neuroprotective effects directly to the central nervous system (CNS). Peptides target specific neurotransmitter systems, providing opportunities for the treatment of diseases, including Alzheimer's, Parkinson's, and multiple sclerosis. In oncology, peptide therapeutics represent a fast-growing area, with peptides being investigated for their anti-cancer properties, including direct cytotoxic effects on cancer cells, inhibition of angiogenesis, and vehicles for targeted drug delivery. Tumor-homing peptides are able to selectively deliver chemotherapeutic agents or radionuclides to tumor cells, minimizing damage to healthy tissues and enhancing treatment efficacy.

End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions

In hospitals & clinics, peptide therapeutics are primarily utilized for direct patient care. They are employed in treating numerous conditions, including cancer, metabolic disorders, cardiovascular diseases, and infectious diseases. Peptide drugs offer a targeted approach to treatment due to their high specificity and potency with relatively low toxicity, allowing for higher efficacy with potentially fewer side effects compared to traditional small molecule drugs. Their application in hospitals & clinics continuously evolves with advances in peptide engineering and drug delivery technologies, enhancing their effectiveness and patient compliance. Long-term care facilities prioritize treatments that ensure the well-being of patients over extended periods, often focusing on management rather than cure. Peptide therapeutics used in long-term care facilities need to have minimal side effects and require less frequent dosing schedules to accommodate the caregiving environment. Research laboratories are crucial in the early stages of peptide therapeutic development. Researchers focus on identifying new bioactive peptides, elucidating their mechanisms of action, and optimizing their properties for therapeutic use. This involves cutting-edge molecular biology, biochemistry, and pharmacology techniques to design, synthesize, and assess the activity of peptide candidates.

Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly

Contract manufacturing organizations provide essential services in the production of peptide therapeutics, serving pharmaceutical and biotech companies that either do not possess the necessary in-house production facilities or choose to outsource manufacturing to focus on core competencies. CMOs offer various services, from synthesizing peptides in small quantities for research purposes to large-scale production for commercial use. They possess the technical expertise, advanced technologies, and regulatory knowledge required for the efficient and compliant manufacture of peptide therapeutics. In-house production refers to the scenario where pharmaceutical or biotechnology companies have the facilities and resources to manufacture peptide therapeutics. This approach allows companies to maintain direct control over the production processes, quality control, and supply chain management, potentially reducing risks associated with reliance on external suppliers. Large pharmaceutical companies often establish in-house production facilities with the financial resources to invest in the necessary infrastructure and skilled personnel. This model facilitates closer integration between research and development activities and manufacturing, which can be advantageous in rapidly evolving therapeutic areas.

Regional Insights

The peptide therapeutics market is evolving in the Americas due to well-established pharmaceutical industries, increased research activities, and a growing number of approved peptide drugs. Patent activity in this region is notable, with several major pharmaceutical companies headquartered in the area. In recent years, investments in innovative peptide formulations have increased, indicating a robust market potential for new therapeutic approaches. The rising prevalence of chronic disease, improving healthcare infrastructure, and growing awareness regarding peptide therapeutics are encouraging the growth of the peptide therapeutics market in the APAC region. In addition, ongoing advancements and the development of efficient, scalable, and cost-effective synthetic strategies for producing peptides are anticipated to encourage the adoption of peptide therapeutics globally. The peptide therapeutics market is developing in the EMEA region owing to the regulatory framework supporting innovation within biotechnology and funding research projects related to peptide therapeutics. The European Union demonstrates a well-established market for peptide therapeutics, supported by comprehensive healthcare systems and a high degree of awareness regarding advanced treatment options. The EU's regulatory framework, through the European Medicines Agency (EMA), has been instrumental in approving and monitoring peptide-based drugs. The peptide therapeutics market in the African region is currently growing steadily, characterized by growing research activities and increasing awareness toward advanced therapeutic options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Peptide Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Peptide Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Hybrid Phase
    • Liquid Phase
    • Solid Phase
  • Drug Class
    • Adrenocorticotropic Hormone
    • Calcitonin
    • Insulin
    • Leuprorelin
    • Octreotide
    • Vasopressin
  • Route of Administration
    • Intravenous Administration
    • Nasal & Pulmonary Administration
    • Oral Administration
    • Transdermal Administration
  • Application
    • Cardiovascular Disorders
    • Gastrointestinal Disorders
    • Infectious Disorders
    • Neurological Disorders
    • Oncology
  • End User
    • Hospitals & Clinics
    • Long-term Care Facilities
    • Research Laboratories
  • Manufacturing Type
    • Contract Manufacturing Organization
    • In-house
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • Indiana
        • Maryland
        • Massachusetts
        • Minnesota
        • New Jersey
        • New York
        • North Carolina
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Peptide Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Peptide Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Peptide Therapeutics Market?

4. What is the market share of the leading vendors in the Peptide Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Peptide Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
      • 5.1.1.2. Exponential use of peptides in aesthetic dermatology
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of peptide therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for new peptide development worldwide
      • 5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
    • 5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
    • 5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
    • 5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
    • 5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
    • 5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
  • 5.3. Market Trend Analysis
    • 5.3.1. Expanding pharmaceutical R&D activities and growing government investment to strengthen the healthcare sector in the Americas
    • 5.3.2. Significant public and private investment in advanced research facilities and technologies in the Asia-Pacific region
    • 5.3.3. Enhancement in peptide manufacturing capabilities, exploring new application areas, and presence of major players in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Peptide Therapeutics Market, by Technology

  • 6.1. Introduction
  • 6.2. Hybrid Phase
  • 6.3. Liquid Phase
  • 6.4. Solid Phase

7. Peptide Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Adrenocorticotropic Hormone
  • 7.3. Calcitonin
  • 7.4. Insulin
  • 7.5. Leuprorelin
  • 7.6. Octreotide
  • 7.7. Vasopressin

8. Peptide Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous Administration
  • 8.3. Nasal & Pulmonary Administration
  • 8.4. Oral Administration
  • 8.5. Transdermal Administration

9. Peptide Therapeutics Market, by Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Disorders
  • 9.3. Gastrointestinal Disorders
  • 9.4. Infectious Disorders
  • 9.5. Neurological Disorders
  • 9.6. Oncology

10. Peptide Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals & Clinics
  • 10.3. Long-term Care Facilities
  • 10.4. Research Laboratories

11. Peptide Therapeutics Market, by Manufacturing Type

  • 11.1. Introduction
  • 11.2. Contract Manufacturing Organization
  • 11.3. In-house

12. Americas Peptide Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Peptide Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Peptide Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
    • 15.3.2. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
    • 15.3.3. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
    • 15.3.4. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
    • 15.3.5. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
    • 15.3.6. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
    • 15.3.7. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
    • 15.3.8. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
    • 15.3.9. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
    • 15.3.10. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
    • 15.3.11. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service

16. Competitive Portfolio

  • 16.1. Key Company Profiles
  • 16.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PEPTIDE THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2030 (%)
  • FIGURE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 22. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 28. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LEUPRORELIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NASAL & PULMONARY ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 313. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY MANUFACTURING TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 326. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)

TABLE